USC engineers developed SHIFTERS, a system using focused ultrasound to help CAR-T cells target solid tumors by inducing temporary CD19 markers.
Key Details
- 1SHIFTERS uses focused ultrasound to prompt tumor cells to express CD19, a marker recognized by CAR-T cells.
- 2The approach exploits tumor hypoxia, requiring both hypoxic conditions and ultrasound for activation (dual-key system).
- 3Tested in cell cultures, 3D tumor models, and animal models with brain and liver tumors, leading to dramatic tumor shrinkage when combined with CAR-T therapy.
- 4Effective immune response was observed even when only 10-25% of tumor cells expressed the temporary marker.
- 5Delivery of the SHIFTERS genetic program is still experimental, using lipid nanoparticles or modified viruses.
- 6The technology remains preclinical and is several years from human trials, requiring further technical advances and funding.
Why It Matters
This strategy could overcome a major barrier in applying CAR-T therapy to solid tumors—lack of a specific target—by noninvasively creating one via imaging technology. It highlights a novel convergence between imaging modalities and next-generation cell therapies, potentially expanding therapeutic options for intractable cancers.
Source
EurekAlert
Related News
•EurekAlert
EU Launches €20M CHAIN Project to Advance AI in Cardiovascular Care
The EU launches the CHAIN initiative to build a validated, federated AI ecosystem for cardiovascular health.
•EurekAlert
AI Model Combines ECG and Blood Tests to Spot Heart Transplant Rejection
An AI model integrating ECG data and blood biomarkers predicts heart transplant rejection with high specificity, reducing the need for invasive biopsies.
•EurekAlert
NIH Grant Funds AI Tool for Lung Cancer Discovery at Weill Cornell
Dr. Olivier Elemento receives an NIH Pioneer Award to develop an AI-human hybrid platform for cancer research, initially focusing on lung cancer using imaging and tissue data.